E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008908 |
E.1.2 | Term | Chronic heart failure |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the trial is to establish the efficacy and safety of Alagebrium chloride (ALT-711) in patients with chronic heart failure and an impaired left ventricular ejection fraction (<40%) by measuring the effect on aerobic capacity (VO2-max) at exercise testing. |
|
E.2.2 | Secondary objectives of the trial |
1. Evaluate the effect of ALT-711 on diastolic function measured by tissue velocity imaging (TVI) with echocardiography 2. Evaluate the effect of ALT-711 on systolic function (eye-balling left ventricular ejection fraction) measured with echocardiography 3. Evaluate the effect of ALT-711 on Advanced glycation end-products (AGEs) in tissue measured with skin-autofluorescence and in blood measured with mass spectrometry analysis 4. Evaluate the effect of ALT-711 on Quality of Life (QoL) measured with the Minnesota Living with Heart Failure score 5. Evaluate the effect of ALT-711 on New York Heart Association (NYHA) heart failure class 6. Evaluate the effect of ALT-711 on Patients's and Physician's global assessment scores 7. Evaluate the effect of ALT-711 on levels of N-terminal pro-brain natriuretric peptide (NT-pro-BNP)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• NYHA II-IV heart failure • Echocardiographic ejection fraction ≤ 40% • Duration of heart failure > 3 months • Stable heart failure medical therapy for > 1 months • Patients need to be able to understand content of and willing to provide informed consent
|
|
E.4 | Principal exclusion criteria |
• Patient ≤ 18 years • History of myocardial infarction in previous 6 months • History of stroke/TIA/RIND in previous 6 months • Severe valvular dysfunction • Severe pulmonary disease • History of systemic inflammatory or collagen vascular disease • Active and or treated malignancies within 12 months prior to inclusion • Any significant condition either medical or non-medical that could lead to difficulty complying with the protocol. • Patients on cardiac resynchronisation therapy (CRT) or scheduled for CRT implantation • Pacemaker therapy (unless rescue pacing at ≤ 40 bpm) or scheduled pacemaker implantation • History of valve replacement or surgery • atrial fibrillation (unless paroxysmal) • Uncontrolled diabetes mellitus (HbA1c>9.5%) • Clinically significant renal disturbance (sMDRD calculated GFR≤30 mL/min/1,73m^2) • Clinically significant liver disease (ASAT/ALAT > 2,5 times the upper limit of normal) • Severe anemia at baseline (Hemoglobin <10 g/dl or <6.2 mmol/l) • Use of any investigational drug(s) within 30 days prior to screening • Pregnancy or active breast-feeding (pregnancy test’s will be performed on all female subjects of childbearing potential)* • Active pericarditis/myocarditis • The inability of patients to undergo exercise testing
* All female subjects of childbearing potential (not postmenopausal for at least 1 year or surgically sterilized) must agree not to become pregnant during the duration of the study. Specifically, they must agree to use an appropriate contraceptive regimen. Acceptable regimens include systemic hormones, intrauterine devices and barrier methods (such as cervical caps, male or female condoms, or diaphragms) with concomitant intravaginal spermicide.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary end-point of the study will be aerobic capacity(VO2max) measured at exercise testing. An improvement of 15% of VO2max will be considered as a clinical significant increase. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the last patient’s last visit. In case the study is ended prematurely, the investigator will notify the accredited METC, including the reasons for the premature termination. Within one year after the end of the study, the investigator/sponsor will submit a final study report with the results of the study, including any publications/abstracts of the study, to the accredited METC. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |